Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares shot up 8.7% during trading on Thursday . The company traded as high as $5.79 and last traded at $5.73. 872,802 shares were traded during mid-day trading, an increase of 41% from the average session volume of 618,295 shares. The stock had previously closed at $5.27.

A number of brokerages have commented on CNAT. ValuEngine downgraded Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 4th. Oppenheimer set a $14.00 target price on Conatus Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 1st. Finally, HC Wainwright restated a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Monday, November 5th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Conatus Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $11.80.

The company has a market capitalization of $159.48 million, a PE ratio of -8.75 and a beta of 1.84. The company has a quick ratio of 2.39, a current ratio of 2.39 and a debt-to-equity ratio of 0.83.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $7.67 million during the quarter, compared to the consensus estimate of $9.70 million. Conatus Pharmaceuticals had a negative return on equity of 83.99% and a negative net margin of 52.77%. On average, equities analysts expect that Conatus Pharmaceuticals Inc will post -0.6 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CNAT. The Manufacturers Life Insurance Company boosted its stake in shares of Conatus Pharmaceuticals by 253.0% during the 1st quarter. The Manufacturers Life Insurance Company now owns 22,987 shares of the biotechnology company’s stock worth $135,000 after acquiring an additional 16,476 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Conatus Pharmaceuticals during the 2nd quarter worth about $142,000. MYDA Advisors LLC bought a new stake in shares of Conatus Pharmaceuticals during the 2nd quarter worth about $154,000. LMR Partners LLP bought a new stake in shares of Conatus Pharmaceuticals during the 2nd quarter worth about $311,000. Finally, Wells Fargo & Company MN boosted its stake in shares of Conatus Pharmaceuticals by 63.4% during the 1st quarter. Wells Fargo & Company MN now owns 55,600 shares of the biotechnology company’s stock worth $326,000 after acquiring an additional 21,564 shares in the last quarter. Institutional investors own 33.47% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2018/11/10/conatus-pharmaceuticals-cnat-shares-up-8-7.html.

Conatus Pharmaceuticals Company Profile (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Further Reading: How to Calculate Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.